Skip to content
Jump to main navigation and login
Nav view search
Navigation
Home
About Us
About the Bing Center
Bing Center Staff
Directions / Find Us
News
Bing Center News
Newsletter Archive
Bing Center Spotlight
Events
WM Summits
archive
WM Workshops
Event Calendar
Media
Media Gallery
Patients
Waldenstrom's Macroglobulinemia Clinic
Clinical Trials
WM Clinical Trials Group
WMCTG
Publications
Resources
Related Web Links
How To Help
Contact Us
Search
Search ...
You are here:
Home
Patients
Clinical Trials
Completed Trials
Latest Bing Center News
A Patient's Legacy Gift
“Dana-Farber has given me a second life,” says Lu Kleppinger, who was treated for a rare blood cancer. “We wanted to make the largest impact possible. What greater gift can we give than one to save lives?” Lu and her husband, Tony, wanted to support the research that saved Lu’s life, so they decided to include Dana-Farber in their estate plans as they prepare for retirement. “It’s the ultimate gift,” continues Lu.
Read more..
23rd Annual EHA Meeting - Bing Center Poster Presentations
The 23rd Annual European Hematology Association Congress was held was held June 14-17, 2018 in Stockholm Sweden. The following are the posters presented by the Bing Center for Waldenstrom's Macroglobulinemia.
Read more..
Steven Treon Interview - April 21, 2018, Milan, Italy
Interview with Dr. Steven Treon in Milan Italy, April 21, 2018 on new research and treatments for Waldenstrom's Macroglobulinemia.
Read more..
Dr. Treon Addresses delegates at EMN and WM patients in Northern Italy
Over 800 delegates were present at the First European Myeloma Network Meeting, that took place in Torino, Italy under the auspices of Mario Boccadoro of the University of Torino on April 19-21, 2018.
Read more..
Dr. Zachary Hunter Draws a Crowd in Northern VA/Washington, DC!
Dr. Zachary Hunter, Ph.D. in Pathology and Director of Genomics at the Bing Center for Waldenström’s Macroglobulinemia drew a crowd of over 60 WMers and caregivers for his presentation “Personalized Medicine in Waldenström’s Macroglobulinemia: What It Means and How We Make It Happen” on April 21, 2018, one of our largest number of guests in the four years since the inception of our IWMF Support Group in 2014.
Read more..
US FDA Approves New Imbruvica/Ibrutinib Formulation
On February 16, 2018, Imbruvica (ibrutinib) was approved by the US FDA in multiple strengths as a 140, 280, 420, and 460 mg tablet. The new formulations are now commercially available, and the original 140 mg capsule will no longer be available after May 15, 2018. Please see the full Prescribing Information (link is external) for indications, dosage and usage.
Read more..
Online WM Workshop - Progress in the Treatment of WM
On Wednesday, June 27th, 2018 from 1:30PM – 2:30PM EST, Dr. Jorge Castillo of Dana-Farber Cancer Institute and Dr. Morie Gertz of Mayo Clinic will engage in a discussion on “Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM).” The program is free, but you must register to participate. https://www.iwmf.com/news-and-events/news/sign-free-iwmf-cancercare-onlinephone-wm-workshop-0
Read more..
5th International Patient and Physician Summit on WM
Dear Friends: It is with great pleasure to invite you to the 5th International Patient and Physician Summit on Waldenstrom’s Macroglobulinemia (WM). The Summit will take place on October 13-14, 2018, at the New York Marriott Downtown Hotel and Conference Center, situated in Lower Manhattan next to the Freedom Tower.
Read more..
59th Annual ASH Meeting - Bing Center Poster Presentations
The 59th Annual ASH meeting & exposition was held was held December 9-12, 2017 in Atlanta, GA. The following are the 16 posters presented by the Bing Center for Waldenstrom's Macroglobulinemia.
Read more..
Special Presentation on Waldenstrom’s Macroglobulinemia Feb 3, 2017
Dr. Steven Treon, from the Dana-Farber Cancer Institute, is coming to Sarasota! Dr. Treon will be sharing an update on the current advances in clinical and laboratory research from the Bing Center for Waldenstrom’s Macroglobulinemia. Dr. Luis Chu, of Florida Cancer Specialists & Research Institute, Sarasota, will also be available for questions.
Read more..
Completed Trials
The clinical trials listed below have been completed and are closed to enrollment:
Title
Rituximab plus Fludarabine for patients with WM
Phase-2: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Phase II Study of VELCADE (PS-341) in WM
Phase II Study of Thalidomide and Rituximab for patients with WM
Phase II Study of Simvastatin in WM
Phase II Study of Perifosine in Patients with Relapsed/Refractory WM
Phase II Study of Imatinib Mesylate (Gleevec) in Relapsed or Refractory WM
Phase II Study of Combination Therapy with bortezomib and rituximab in patients with relapsed/refractory Waldenstrom’s macroglobulinemia.
Phase II Study of CC-5013 (Lenalidomide , Revlimid(tm)) and rituximab in Waldenstrom's macroglobulinemia
Phase II Clinical Trial of Sildenafil Citrate in WM
Phase II Clinical Trial of RAD001 in relapsed/refractory lymphoma
Phase II Clinical Trial of combination therapy with bortezomib, dexamethasone, and rituximab in patients with WM
Extended Rituximab for patients with WM
Campath-1H for patients with relapsed and refractory WM
An Open Label, Multicenter Phase-2 Study of Single-Agent Enzastaurin HCl in Previously Treaed Waldenstrom's Macroglobulinemia or Multiple Myeloma
